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Introduction
For nearly 50 years uterine smooth muscle tumours fulfilling some, but not all, of the pathological criteria for uterine leiomyosarcoma (LMS) have been diagnostically and clinically challenging [1] . Smooth muscle tumours of uncertain malignant potential (STUMP) have histopathological features of malignancy falling short of LMS, variably clinically aggressive course and recurrence rates of 4.6% to 26.7% depending on histopathological criteria employed [2] . These characteristics have generated considerable management and treatment uncertainty and necessitated prolonged periods of follow-up [1, 3] At the molecular level, aberrant immunohistochemical expression of p53 and p16 INK4A have been investigated as prognostic and diagnostic tools and are correlated with poorer prognosis in some studies [4] Telomere maintenance is an important aspect of the replicative capacity inherent in neoplasia, and telomerase inhibitors have been developed as potential targeted therapy [5] . In the normal cell, progressive telomere shortening to a critical length occurs until cell division ceases. This shortening is circumvented in neoplasia by the activation of telomere maintenance [6] . Recent progress in the molecular subtyping of mesenchymal tumours has identified prognostic implications in the type of telomere maintenance mechanism employed. The presence of alternative lengthening of telomeres (ALT) maintenance portends a better prognosis in glioblastoma multiforme compared with telomerase activation in these tumours [7] , but a worse prognosis in many soft tissue sarcomata [8] . ALT maintenance has been demonstrated in uterine LMS as a poor prognostic indicator [9] [10] . ALT telomere maintenance tumours may also respond differently to treatment, especially radiotherapy [11] .
ALT maintenance in pancreatic neuroendocrine tumours and pediatric glioblastoma multiforme has been shown to closely correlate with the presence of a mutation in ATRX and DAXX genes [12, 13] . In glioblastoma multiforme ALT tumours were associated with simultaneous mutations in ATRX-DAXX, p53 and H3F3A [14] . The ATRX and DAXX proteins are demethylases involved in remodeling of chromatin structure. The alteration of chromatin architecture through the inhibition of demethylation by ATRX and DAXX dysfunction has been reported to underlie ALT activation in gliomagenesis [14] . Isocitrate dehydrogenase (IDH) mutations have also been identified in association with ALT activation in tumours [15, 16] .
ALT TMM produces extremely long and heterogeneous telomere lengths and multiprotein structures called ALT-associated PML bodies (APBs). Evaluation of ALT by APB detection as well as ATRX and DAXX immunohistochemistry (IHC) was conducted to explore their development as reproducible histopathological tools, thereby enhancing diagnosis and predicting clinical progress of smooth muscle tumours. The profile of the ALT associated R132H IDH1 mutation was studied to provide a biological basis for its application as a radiological diagnostic and therapeutic tool.
We hypothesized that ALT telomere maintenance identifies clinically aggressive tumours prone to recurrence and death and that ALT maintenance was an early tumourigenic change. This would prove useful for diagnostically difficult tumours (STUMP) and clinically useful prior to emergent metastatic disease (stage 1 LMS) for therapeutic management and follow-up. Tumour protein p53 and p16
INK4A IHC was also studied to further define their diagnostic utility in a larger cohort than had previously been examined.
Methods
Patients with uterine smooth muscle tumours at Dunedin and Tauranga [4] , based on the presence of necrosis, nuclear atypia, margin and mitotic activity. Five of the variant LM were cellular and one was mitotically active but without cytological atypia or tumour cell necrosis. The presence of diffuse or multifocal moderate to severe cytologic atypia and <10 mitoses per 10HPFs, tumour cell necrosis but no other worrisome features or >15 mitoses per 10HPFs but no other worrisome features, defined each STUMP case, and are illustrated in Figure 1 . STUMP case 6 was a mixed spindle and myxoid tumour with mitotically active spindle cell component but with low (<0/10HPF) mitotic count in the myxoid component, and thus fell short of criteria for a myxoid LMS. Similarly, case 8 was a mixed spindle and epithelioid tumour, but with less than 50% epithelioid component, thus falling short of criteria for an epithelioid LMS [4] . As no criteria exist for the diagnosis of a vaginal STUMP, we have applied the uterine criteria to two vaginal cases in an effort to better characterize these rare tumours. Seven of the 18 cases of STUMP had previously been reported by two of us [2] . LMS were classified according to WHO criteria [17] .
IHC analyses
IHC reactions were performed using standard techniques: paraffin embedded tissue sections, heat-mediated antigen retrieval and antibody detection by EDL (Dako, Glostrup, Denmark) and DAB according to the manufacturers' instructions. p53 expression was determined using DO-7 (Cell Marque, Rockin, CA) at a 1 in 50 dilution. p16
Mutant IDH1 was detected using the anti-Human IDH1 R132H specific mouse monoclonal antibody HO-9 (Dianova, Hamburg, Germany) diluted 1 in 50. ATRX was detected using HPA001906 (SigmaAldrich, St Louis, MO) diluted 1 in 700. DAXX was performed using a 1 in 100 dilution HPA008736 (Sigma-Aldrich, St Louis, MO). Cells were imaged using light microscopy (DM 2000 microscope, DFC 295 camera and Application Suite software, version 3.5.0, Leica, Solms, Germany). The slides were assessed by four surgical pathologists (PI, AC, NH and TS) independently. A tumour was considered positive for p53 when either no tumour cell staining was evident, or greater than 80% of the tumour cells were positively stained. IDH1 was considered positive when 10% or more of the tumour nuclei were moderately stained by IHC. IHC for p16
INK4A expression was performed in a limited cohort of 36 cases (15/ 18 STUMP and 24/43 LMS). Greater than 70% nuclear staining at intensity greater than adjacent normal vascular smooth muscle was interpreted as p16
INK4A
, overexpression ( Figure 2) . Ten percent or less nuclear staining in more than 50% of the tumour for ATRX or DAXX protein determined loss of expression. Cell nuclei of endothelial and vascular smooth muscle from normal tissue in the sections served as an internal control for ATRX or DAXX protein expression (thus normal cell nuclear staining of these nuclei was expected within the tumour, Figure 2 ).
APB detection
The APB detection method used in this study is a modified version of the method used by Yeager et al. (1999) and Henson et al. (2005) and our specific methodology has been reported in earlier studies [8, 18, 19] . Briefly, slides were incubated an anti-PML rabbit polyclonal primary antibody (H-238, Santa Cruz Biotechnology, Santa Cruz SD) using a 1 in 500 dilution and detected with an Alexa Fluor 488 antibody (Life Technologies, Carlsbad, CA). Telomere DNA was detected using a Cy3-labelled PNA probe 5 0 -CCCTAACCCTAACCCTAA-3 0 (Life Technologies, Carlsbad, CA). The cellular nuclei were stained using DAPI. Cells were imaged using confocal microscopy (Zeiss LSM510; Carl Zeiss, Thornwood, NY). For each colocalized signal, the fluorescent signal from each channel was analysed using the software Zeiss LSM Image Examiner (Version 30115; Carl Zeiss Thornwood, NY). A tumour was designated APB positive when a colocalized focus of telomeric DNA and PML protein within the Figure 1 . A to C: Three cases of STUMP that were followed by a recurrence. These have moderate to high cellularity, multifocal moderate atypia and <or=<10 mitoses/10 HPFs. D: Leiomyosarcoma with marked atypia and tumour cell necrosis.
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nucleus was identified in ! 5% of the cells. One APB in a cell nucleus qualified the cell as positive. APBs were interpreted as bright yellow colocalized areas with a clear peak signal of at least 100 relative fluorescent intensity ( Figure 2 ).
Statistical analyses
Correlations between categorical variables were analysed with the v 2 test with p < 0.05 taken as statistically significant. Descriptive statistics of patients and their tumours, and the frequencies of observing each variant (i.e., prospective marker) among patients in each tumour cohort were prepared. The risk of outcome event among patients with each marker was estimated using univariate Cox regression. Cases with unknown outcome status were considered as censored in these time-to-event analyses.
Results
The clinical characteristics of the cases are summarized in Table 1 . Patients with LM were treated by hysterectomy or surgical excision alone. None of these patients had a recurrence. Patients with a STUMP diagnosis underwent hysterectomy or surgical excision alone (one case underwent myomectomy only). None of the patients with a uterine STUMP diagnosis received radiation or chemotherapy at the time of diagnosis. In this cohort four women (25%) had first recurrence at mean 49 months, and three women (18.7%) had died of disease at 56, 60 and 140 months post diagnosis. In the LMS cohort, nearly half of the women (49%) had a recurrence or had died, with mean recurrence or death at 32 months. However, the longest recurrence-free survival was 11 years (case 13). The follow-up period totaled 2567 person-months without recurrence, 1243.5 person-months with recurrence, 2742 person-months death not observed and 1199.5 person-months among patients who died of disease. The STUMP cases were followed for a mean of 70 months (median 58 months, range 1-140 months) until recurrence or death, and 85.4 months (median 85 months, range 6-168 months) for no evidence of disease. The LMS cases were followed a mean of 35 months (median 22 months, range 1-138 months) until recurrence or death, and 78 months (median 78 months, range 1-156 months) for no evidence of disease. The uterine STUMP cases recurred later (mean 49 months, 95% CI 47, 51) compared to recurrent LMS cases (mean 22.3 months, 95% CI 6, 38, p 5 0.02), but both succumbed in a similar period (STUMP 76 months, 95% CI 9, 143 versus LMS mean 98 months, 95% CI 78-117, p 5 0.07). For patients who presented in stage 1 LMS at diagnosis (n 5 23), 35% had died by 10 years follow-up (114 months) and two patients were alive with disease at 23 and 78 months follow-up.
In the STUMP cohort the predominant histopathological type was spindle cell, except for two mixed spindle cases (with <50% area of epithelioid component, and myxoid admixed). The LMS cases were also predominantly spindle cell type (72%, with epithelioid, myxoid or mixed types in the remaining). Neither age nor tumour size was significantly different between the STUMP and LMS cases (p 5 0.10 and p 5 0.18). The mitotic rate, however, was significantly lower in the STUMP group (p < 0.0001) as expected with required diagnostic criterion of less than 10 mitoses per 10HPF. The individual features are given in Tables 2 and 3 .
All tumours were screened for APB presence, p53 aberrant expression (a surrogate for p53 mutation), IDH1 R132H mutation expression and ATRX or DAXX expression loss to determine the ALT phenotype. A subset of 24 LMS and 15 STUMP were also screened for p16
INK4A overexpression by IHC. We refer to each of these as the molecular variants. No molecular variant was identified as specific to the spindled, epithelioid or myxoid subtypes. Examples of p16
INK4A overexpression, p53 expression, IDH1 R132H mutation expression, loss of expression of ATRX or DAXX, no loss of expression for ATRX or DAXX (no evidence of mutation), and APB presence determination are given in Figure 2A -F. None of the LM cases demonstrated a molecular variant, except for one case with IDH1 R132H mutation expression.
The ALT phenotype was found in STUMP and LMS but not in LM or variant LM cases Amongst the 22 STUMP and LMS cases that were ALT positive as determined by APB presence, 20 had ATRX or DAXX loss (p < 0.0001). Thus, ALT was highly associated with ATRX and DAXX expression loss commensurate with the presence of mutations. Only one LMS case was APB positive with no loss of ATRX or DAXX expression. Another 19.6% (12/61) of STUMP and LMS showed ATRX or DAXX expression loss without APB presence. Only three LMS cases were DAXX negative and the remaining cases were ATRX negative. No STUMP and 14% (6/43) of LMS cases showed IDH1 R132H mutation expression. Poor prognosis uterine smooth muscle tumours 99 Tables 2 and 3 . At least one molecular variant was found in the majority of tumours with recurrence or death.
The STUMP group was too small for the statistical analysis of survival. Univariate Cox regression showed that, for overall survival in the LMS group, loss of ATRX or DAXX expression identified poor prognosis (CI 2.1 to 40, p < 0.003) and, for progression free survival, loss of ATRX or DAXX expression was statistically significant (CI 2.2 to 25, p 5 0.001). We were limited in our analysis of p16 INK4A IHC due to tissue availability but p16
INK4A
overexpression was narrowly significant (CI, 0.3 to 0.9, p 5 0.047). Aberrant p53 expression did not reach significance.
Discussion
The homologous recombination based ALT mechanism is found predominantly in mesenchymal malignancies [20] . This is the largest study to date examining ALT maintenance molecular markers with recurrence and survival time in smooth muscle tumours of the uterus. In particular, we examine early stage LMS and tumours that are diagnostically problematic.
Although APB determination is a well-tested marker of ALT TMM, the detection method involves combined FISH and IHC techniques, requiring particular expertise and time and some exceptions do occur [19] . Furthermore, in our hands, APB presence was not as significant as ATRX or DAXX expression loss. ATRX or DAXX loss appears to occur early in tumourigenesis and this could explain why some tumours with ATRX or DAXX expression loss were not ALT positive or p53 expression aberrant. The association of ATRX or DAXX expression loss with a higher proliferation rate (p 5 0.0003) and pronounced cytological atypia provides a molecular basis for the histopathological assessment.
Immunohistochemical staining is widely used as a surrogate for ATRX and DAXX mutation [12, 13, 21, 22] . This does not prove mutation and is less sensitive on small-sized tissue microarrays compared to sequence based methods to identify ATRX mutations directly [22] . However, with awareness of tumour heterogeneity, interpretation is straightforward and IHC is a practical test in the diagnostic workup [12, 13] .
Tumours that lose ATRX or DAXX but maintain wild-type p53 may respond better to DNA damaging agents. In a recent study loss of ATRX sensitized cells to 5-fluorouracil and cisplatin treatment by p53 mediated cell death [11] . In our study one uterine STUMP and 14 LMS had loss of ATRX or DAXX expression and wild-type p53 IHC expression, and thus both recurrent STUMP and LMS could potentially respond to DNA damaging treatment. However, for patients with ATRX or DAXX expression loss, the associated mutant p53 in their tumours may make such treatment ineffective.
The acquisition of the R132H IDH1 mutation leads to an alteration in catalytic ability and the production of an oncometabolite, R(-)-2-hydroxyglutarate (2-HG) that inhibits histone demethylases and indirectly affects H3F3A methylation [23] [24] [25] . Furthermore, 2-HG has been identified by noninvasive imaging [26] , and tumours with the mutant enzyme may be susceptible to chemotherapy [27] . The R132H IDH1 mutation precedes mutation of p53, which appears to be the Poor prognosis uterine smooth muscle tumours
